Appili Therapeutics to Present at Maxim Group’s Infectious Disease Virtual Conference

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will be a panelist at the upcoming “Infectious Disease Virtual Conference” presented by Maxim Group. Dr. Balboni will be discussing Appili’s ATI-2307 program, a novel antifungal for resistant infections that the Company acquired from FUJIFILM Toyama Chemical in 2019. The conference, called, The Renaissance of the Anti-infective Sector, will occur online on Tuesday, May 5, 2020.

Presentation details are as follows:

• Date: Tuesday, May 5, 2020
• 12:15 – 1:45 p.m. ET
• Panel: Antifungals

About the Conference

The conference consists of four panels of companies in various stages of development, from early stage to near commercialization, that represent the next wave of innovation in the infectious disease sector. While COVID-19 has captured the world's attention for now, there is another pandemic that has been smoldering beneath the surface; drug resistant bacteria and fungi driving alarming rates of invasive disease, which result in high rates of mortality and a significant burden on the healthcare system. The lag in development of novel anti-infectives is multi-factorial, but moving through 2020 and beyond, there is a renaissance in drug development taking place that has not been observed for some time. This includes novel drugs and new drug classes, changes in regulatory guidelines and incentives for drug developers, changes to clinical trial design and execution, changes in views from payers and the investment community.

About Appili Therapeutics

Appili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this critical disease space. Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape. This diverse pipeline aims to address some of the most urgent threats in global public health, including ATI-2307, a novel, broad spectrum, clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections; ATI-1701, a vaccine candidate for tularemia, a very serious biological weapons threat; ATI-1503, a drug discovery program aimed at generating a novel class of antibiotics with broad-spectrum activity against Gram-negative superbugs; and ATI-1501, which employs Appili’s proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of patients with difficulty swallowing. Headquartered in Halifax, Nova Scotia, with offices in Toronto, Ontario, Appili is pursuing worldwide opportunities in collaboration with scientific and industry commercial partners, governments and government agencies. For more information, visit www.AppiliTherapeutics.com.